Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:EMCNYSEAMERICAN:PFNXTSE:PLINASDAQ:TLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEMCEMC$29.29-0.1%$0.00$22.99▼$29.13N/AN/A13.90 million shs5,025 shsPFNXPfenex$12.75$12.75$5.26▼$14.00$437.29MN/A503,865 shsN/APLIProMetic Life SciencesC$0.00C$7.13▼C$590.00C$317.06MN/A8,002 shs921 shsTLXTelix Pharmaceuticals$16.12-2.3%$16.97$13.61▼$30.36$5.58BN/A28,587 shs31,814 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEMCEMC-0.04%+0.64%+6.51%+11.03%+8.07%PFNXPfenex0.00%0.00%0.00%0.00%0.00%PLIProMetic Life Sciences0.00%0.00%0.00%0.00%0.00%TLXTelix Pharmaceuticals+2.61%+3.19%-1.79%+2.17%+1,649,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEMCEMCN/AN/AN/AN/AN/AN/AN/AN/APFNXPfenexN/AN/AN/AN/AN/AN/AN/AN/APLIProMetic Life SciencesN/AN/AN/AN/AN/AN/AN/AN/ATLXTelix PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEMCEMC 0.00N/AN/AN/APFNXPfenex 0.00N/AN/AN/APLIProMetic Life Sciences 0.00N/AN/AN/ATLXTelix Pharmaceuticals 3.00Buy$22.3338.51% UpsideCurrent Analyst Ratings BreakdownLatest PFNX, TLX, PLI, EMC, and SPL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025TLXTelix PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$23.006/12/2025TLXTelix PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$22.006/5/2025TLXTelix PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$22.00(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEMCEMCN/AN/AN/AN/AN/AN/APFNXPfenexN/AN/AN/AN/AN/AN/APLIProMetic Life SciencesC$39.91M0.00N/A3.94C$6.07 per share0.00TLXTelix Pharmaceuticals$516.72M10.56$0.11 per share144.49$1.12 per share14.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEMCEMCN/A$2.0514.29∞N/AN/AN/AN/AN/APFNXPfenexN/AN/A0.00∞N/AN/AN/AN/AN/APLIProMetic Life SciencesN/A-C$63.06N/AN/AN/AN/AN/AN/AN/ATLXTelix Pharmaceuticals$32.93MN/A0.0033.59N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEMCEMC$0.461.57%N/A22.44%N/APFNXPfenexN/AN/AN/AN/AN/APLIProMetic Life SciencesN/AN/AN/AN/AN/ATLXTelix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEMCEMCN/AN/AN/APFNXPfenexN/AN/AN/APLIProMetic Life Sciences37.474.063.66TLXTelix Pharmaceuticals0.992.782.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEMCEMC79.86%PFNXPfenexN/APLIProMetic Life SciencesN/ATLXTelix PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipEMCEMC0.40%PFNXPfenexN/APLIProMetic Life SciencesN/ATLXTelix PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEMCEMCN/AN/AN/ANot OptionablePFNXPfenex7134.30 millionN/ANot OptionablePLIProMetic Life Sciences48723.31 millionN/ANot OptionableTLXTelix PharmaceuticalsN/A338.38 millionN/AN/APFNX, TLX, PLI, EMC, and SPL HeadlinesRecent News About These CompaniesTelix Pharmaceuticals Stock Short Interest Report | NASDAQ:TLX - BenzingaJuly 3 at 5:30 PM | benzinga.comHC Wainwright & Co. Initiates Coverage of Telix Pharmaceuticals Limited - Depositary Receipt () (TLX) with Buy RecommendationJuly 3 at 5:30 PM | msn.comTelix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Here's What HappenedJuly 3 at 12:48 PM | marketbeat.comTelix Pharmaceuticals (NASDAQ:TLX) Coverage Initiated at HC WainwrightJuly 3 at 8:27 AM | marketbeat.comUp 36% in a year, why this $8 billion ASX 200 stock has still a 'strong growth forecast'June 30 at 2:24 AM | msn.comTelix Pharmaceuticals (NASDAQ:TLX) Sees Large Volume Increase - Still a Buy?June 29, 2025 | americanbankingnews.comTelix Pharmaceuticals (NASDAQ:TLX) Sees Unusually-High Trading Volume - Here's What HappenedJune 27, 2025 | marketbeat.comTelix Pharmaceuticals Limited: Telix Manufacturing Solutions Belgium Delivers First GMP-Grade Commercial DosesJune 25, 2025 | finanznachrichten.deTelix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - What's Next?June 23, 2025 | marketbeat.comIlluccix Approved in U.S. for Patient Selection for Pre-Taxane RLTJune 23, 2025 | globenewswire.comTelix Pharmaceuticals (NASDAQ:TLX) Sees Large Volume Increase - Time to Buy?June 20, 2025 | marketbeat.comTelix Precision Medicine Announces AlFluor Radiochemistry PlatformJune 20, 2025 | globenewswire.comTelix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025June 19, 2025 | globenewswire.comTelix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Stock Price Down 6.7% - Time to Sell?June 13, 2025 | marketbeat.comTelix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Up - Time to Buy?June 12, 2025 | marketbeat.comTelix Pharmaceuticals Limited American Depositary Shares' (TLX) "Outperform" Rating Reaffirmed at WedbushJune 12, 2025 | marketbeat.comTelix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Down - Time to Sell?June 6, 2025 | marketbeat.comWilliam Blair Has Positive Estimate for TLX FY2025 EarningsJune 6, 2025 | marketbeat.comWedbush Initiates Coverage of Telix Pharmaceuticals Limited - Depositary Receipt () (TLX) with Outperform RecommendationJune 5, 2025 | msn.comTelix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Up - Here's WhyJune 5, 2025 | marketbeat.comTelix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Now Covered by WedbushJune 5, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesApplied Digital: Now the High-Stakes Race to Build BeginsBy Jeffrey Neal Johnson | June 17, 2025View Applied Digital: Now the High-Stakes Race to Build BeginsAddition by Subtraction: Intel’s New Strategy Energizes InvestorsBy Jeffrey Neal Johnson | June 27, 2025View Addition by Subtraction: Intel’s New Strategy Energizes Investors3 Notable Stocks Just Split: Which One Could Be the Big Winner?By Leo Miller | June 26, 2025View 3 Notable Stocks Just Split: Which One Could Be the Big Winner?Chime’s Smart IPO: Half the Valuation, Double the StrengthBy Jeffrey Neal Johnson | June 18, 2025View Chime’s Smart IPO: Half the Valuation, Double the Strength3 Tech Stocks Insiders Are Buying: Speculative Plays for JuneBy Thomas Hughes | June 4, 2025View 3 Tech Stocks Insiders Are Buying: Speculative Plays for JunePFNX, TLX, PLI, EMC, and SPL Company DescriptionsEMC NYSE:EMCEMC Corporation (EMC) develops, delivers and supports the information technology (IT) industry's range of information infrastructure and virtual infrastructure technologies, solutions and services. EMC manages the Company as part of a federation of businesses: EMC Information Infrastructure, VMware Virtual Infrastructure, Pivotal and Virtustream. EMC's Information Infrastructure business provides a foundation for organizations to store, manage, protect, analyze and secure information. EMC's VMware Virtual Infrastructure business is engaged in virtualization and cloud infrastructure solutions that enable businesses to help transform the way they build, deliver and consume IT resources in a manner that is based on their specific needs. EMC's Pivotal business unites strategic technology, people and programs from EMC and VMware and has a platform that consists of data, agile development practices and a cloud independent platform-as-a-service.Pfenex NYSEAMERICAN:PFNX$12.75 0.00 (0.00%) As of 10/1/2020Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.ProMetic Life Sciences TSE:PLIPrometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.Telix Pharmaceuticals NASDAQ:TLX$16.12 -0.38 (-2.28%) As of 03:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
